DEFA14A: Masimo CEO Expresses Confidence in Upcoming Shareholder Vote Amidst Activist Challenge

Masimo's CEO, Joe Kiani, anticipates a favorable outcome in the upcoming shareholder vote, citing concerns over Politan Capital's attempt to gain control of the company and replace him.

Summary

• Masimo's CEO, Joe Kiani, discussed the upcoming shareholder vote and Politan Capital's attempt to gain control of the company at the BofA Securities Health Care Conference.
• Kiani believes Masimo will win the vote because Politan is seeking control with only 9% of the shares, aiming to replace four out of five board members, including Kiani himself.
• Kiani highlighted his role as Founder, CEO, and driver of innovation at Masimo, suggesting that ISS (Institutional Shareholder Services) would likely issue a favorable report.
• Kiani expressed uncertainty about Politan's motives, noting that Politan's representative on the board had made only one suggestion during their tenure.
• Masimo is committed to separating the consumer business, potentially through a spin-off or joint venture, despite Politan's apparent opposition.
• Kiani mentioned that a potential JV partner wanted to finalize a deal by June 25, but Politan's threat of litigation is causing delays.
• Masimo is seeking a new board member to replace Rolf, aiming for someone with a more strategic background.
• The company is prioritizing the wishes of the majority shareholders regarding the separation of the consumer health business.
• Masimo intends to file a proxy statement and GOLD proxy card with the SEC in connection with its solicitation of proxies for its 2024 Annual Meeting.
• The company's directors and certain of its executive officers and employees may be deemed to be participants in connection with the solicitation of proxies from the Company's stockholders in connection with the matters to be considered at the 2024 Annual Meeting.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. The CEO expresses confidence, but there are clear challenges and uncertainties related to the activist investor and the business separation.

Positives

• Masimo is listening to its shareholders regarding the separation of the consumer health business.
• The company is actively seeking a strategic board member to replace Rolf.
• Masimo is committed to the spin-off/JV of the consumer business.

Negatives

• Politan Capital, holding only 9% of shares, is attempting to gain control of the company.
• Politan's actions are causing delays in a potential joint venture, potentially losing momentum.
• The CEO doesn't understand what Politan wants.

Risks

• Uncertainties regarding the potential separation of Masimo's Consumer Business.
• Future actions that may be taken by Politan in furtherance of its nomination of director candidates for election at the 2024 Annual Meeting.
• The potential cost and management distraction attendant to Politans nomination of director nominees at the 2024 Annual Meeting.

Future Outlook

Masimo is evaluating a potential separation of its Consumer Business and the expected timing for completing any joint venture or other separation of Masimos Consumer Business and the potential benefits of any such separation.

Management Comments

• We expect that we'll win [the shareholder vote].
• I don't think they want us to hand the keys over to an activist who's never run anything before.
• I really don't understand what's driving him [Quentin of Politan Capital].
• Yes, 100% committed to doing it [the separation].
• I always say the most important thing to any deal is momentum.

Industry Context

The situation reflects a growing trend of activist investors targeting companies to influence strategy and operations, particularly in the healthcare sector. Masimo's response and the shareholder vote will be closely watched by other companies facing similar challenges.

Comparison to Industry Standards

• The battle between Masimo and Politan Capital mirrors similar activist campaigns seen at companies like Procter & Gamble (Nelson Peltz) and Darden Restaurants (Starboard Value), where activists sought board representation and strategic changes.
• The proposed spin-off of Masimo's consumer business is a strategy employed by other diversified companies like Johnson & Johnson (separation of consumer health business, Kenvue) to unlock value and focus on core operations.
• The level of board influence sought by Politan (4 out of 5 seats with only 9% ownership) is aggressive compared to typical activist demands, which often involve seeking minority representation.

Legal Proceedings

• Politan is threatening litigation if Masimo proceeds with the JV before the proxy vote.

Stakeholder Impact

• Shareholders will be impacted by the outcome of the shareholder vote and the potential separation of the consumer business.
• Employees in the consumer business may be affected by the spin-off or joint venture.
• The company's strategic direction and innovation efforts could be influenced by the composition of the board of directors.

Next Steps

• Masimo will file a proxy statement and GOLD proxy card with the SEC.
• The company will proceed with plans to separate the consumer business, pending the outcome of the shareholder vote and resolution of potential legal challenges.
• Masimo will seek a new board member to replace Rolf.

Key Dates

Keywords

Masimo, Politan Capital, Shareholder Vote, Board of Directors, Joe Kiani, Consumer Business, Spin-off, Joint Venture, Activist Investor, Proxy Statement